Celltrion’s ‘Remsima’ approve from U.S. FDA, challenging KRW 20 trillion market
Celltrion announced acquisition of U.S. sales approval of the first biosimilar antibody Remsima from the U.S. Food and Drug Administration(hereinafter referring to FDA) on April 5(local time).
The FDA particularly approved sales of the drug for every indication the company applied, such as rheum...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
